Penelope Hallett - Publications

Affiliations: 
2002-2006 Neurology Harvard Medical School, Boston, MA, United States 

27 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2015 Rocha EM, Smith GA, Park E, Cao H, Brown E, Hayes MA, Beagan J, McLean JR, Izen SC, Perez-Torres E, Hallett PJ, Isacson O. Glucocerebrosidase gene therapy prevents α-synucleinopathy of midbrain dopamine neurons. Neurobiology of Disease. PMID 26392287 DOI: 10.1016/j.nbd.2015.09.009  0.4
2015 Rocha EM, Smith GA, Park E, Cao H, Graham AR, Brown E, McLean JR, Hayes MA, Beagan J, Izen SC, Perez-Torres E, Hallett PJ, Isacson O. Chronic pharmacological glucocerebrosidase inhibition induces α-synuclein aggregation, microglial and complement activation and synaptic protein changes in mice. Antioxidants & Redox Signaling. PMID 26094487 DOI: 10.1089/ars.2015.6307  0.4
2015 Smith GA, Rocha EM, Rooney T, Barneoud P, McLean JR, Beagan J, Osborn T, Coimbra M, Luo Y, Hallett PJ, Isacson O. A Nurr1 agonist causes neuroprotection in a Parkinson's disease lesion model primed with the toll-like receptor 3 dsRNA inflammatory stimulant poly(I:C). Plos One. 10: e0121072. PMID 25815475 DOI: 10.1371/journal.pone.0121072  0.4
2015 Hallett PJ, Deleidi M, Astradsson A, Smith GA, Cooper O, Osborn TM, Sundberg M, Moore MA, Perez-Torres E, Brownell AL, Schumacher JM, Spealman RD, Isacson O. Successful function of autologous iPSC-derived dopamine neurons following transplantation in a non-human primate model of Parkinson's disease. Cell Stem Cell. 16: 269-74. PMID 25732245 DOI: 10.1016/j.stem.2015.01.018  0.4
2014 Hallett PJ, Cooper O, Sadi D, Robertson H, Mendez I, Isacson O. Long-term health of dopaminergic neuron transplants in Parkinson's disease patients. Cell Reports. 7: 1755-61. PMID 24910427 DOI: 10.1016/j.celrep.2014.05.027  0.4
2014 McLean JR, Smith GA, Rocha EM, Osborn TM, Dib S, Hayes MA, Beagan JA, Brown TB, Lawson TF, Hallett PJ, Robertson J, Isacson O. ALS-associated peripherin spliced transcripts form distinct protein inclusions that are neuroprotective against oxidative stress. Experimental Neurology. 261: 217-29. PMID 24907400 DOI: 10.1016/j.expneurol.2014.05.024  0.4
2014 McLean JR, Smith GA, Rocha EM, Hayes MA, Beagan JA, Hallett PJ, Isacson O. Widespread neuron-specific transgene expression in brain and spinal cord following synapsin promoter-driven AAV9 neonatal intracerebroventricular injection. Neuroscience Letters. 576: 73-8. PMID 24882721 DOI: 10.1016/j.neulet.2014.05.044  0.4
2014 Smith GA, Rocha EM, McLean JR, Hayes MA, Izen SC, Isacson O, Hallett PJ. Progressive axonal transport and synaptic protein changes correlate with behavioral and neuropathological abnormalities in the heterozygous Q175 KI mouse model of Huntington's disease. Human Molecular Genetics. 23: 4510-27. PMID 24728190 DOI: 10.1093/hmg/ddu166  0.4
2014 Davies SE, Hallett PJ, Moens T, Smith G, Mangano E, Kim HT, Goldberg AL, Liu JL, Isacson O, Tofaris GK. Enhanced ubiquitin-dependent degradation by Nedd4 protects against α-synuclein accumulation and toxicity in animal models of Parkinson's disease. Neurobiology of Disease. 64: 79-87. PMID 24388974 DOI: 10.1016/j.nbd.2013.12.011  0.4
2013 Sundberg M, Bogetofte H, Lawson T, Jansson J, Smith G, Astradsson A, Moore M, Osborn T, Cooper O, Spealman R, Hallett P, Isacson O. Improved cell therapy protocols for Parkinson's disease based on differentiation efficiency and safety of hESC-, hiPSC-, and non-human primate iPSC-derived dopaminergic neurons. Stem Cells (Dayton, Ohio). 31: 1548-62. PMID 23666606 DOI: 10.1002/stem.1415  0.4
2012 Hallett PJ, McLean JR, Kartunen A, Langston JW, Isacson O. α-Synuclein overexpressing transgenic mice show internal organ pathology and autonomic deficits. Neurobiology of Disease. 47: 258-67. PMID 22549133 DOI: 10.1016/j.nbd.2012.04.009  0.4
2012 McLean JR, Hallett PJ, Cooper O, Stanley M, Isacson O. Transcript expression levels of full-length alpha-synuclein and its three alternatively spliced variants in Parkinson's disease brain regions and in a transgenic mouse model of alpha-synuclein overexpression. Molecular and Cellular Neurosciences. 49: 230-9. PMID 22155155 DOI: 10.1016/j.mcn.2011.11.006  0.4
2011 Deleidi M, Hargus G, Hallett P, Osborn T, Isacson O. Development of histocompatible primate-induced pluripotent stem cells for neural transplantation. Stem Cells (Dayton, Ohio). 29: 1052-63. PMID 21608081 DOI: 10.1002/stem.662  0.4
2010 Deleidi M, Hallett PJ, Koprich JB, Chung CY, Isacson O. The Toll-like receptor-3 agonist polyinosinic:polycytidylic acid triggers nigrostriatal dopaminergic degeneration. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 30: 16091-101. PMID 21123556 DOI: 10.1523/JNEUROSCI.2400-10.2010  0.4
2010 Hargus G, Cooper O, Deleidi M, Levy A, Lee K, Marlow E, Yow A, Soldner F, Hockemeyer D, Hallett PJ, Osborn T, Jaenisch R, Isacson O. Differentiated Parkinson patient-derived induced pluripotent stem cells grow in the adult rodent brain and reduce motor asymmetry in Parkinsonian rats. Proceedings of the National Academy of Sciences of the United States of America. 107: 15921-6. PMID 20798034 DOI: 10.1073/pnas.1010209107  0.4
2010 Silverdale MA, Kobylecki C, Hallett PJ, Li Q, Dunah AW, Ravenscroft P, Bezard E, Brotchie JM. Synaptic recruitment of AMPA glutamate receptor subunits in levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate. Synapse (New York, N.Y.). 64: 177-80. PMID 19852073 DOI: 10.1002/syn.20739  0.4
2009 Chung CY, Koprich JB, Hallett PJ, Isacson O. Functional enhancement and protection of dopaminergic terminals by RAB3B overexpression. Proceedings of the National Academy of Sciences of the United States of America. 106: 22474-9. PMID 20007772 DOI: 10.1073/pnas.0912193106  0.4
2009 Hallett PJ, Cooper O, Isacson O. No evidence for disease-like processes in fetal transplants. Proceedings of the National Academy of Sciences of the United States of America. 106: E104; author reply E. PMID 19805203 DOI: 10.1073/pnas.0908169106  0.4
2009 Astradsson A, Jenkins BG, Choi JK, Hallett PJ, Levesque MA, McDowell JS, Brownell AL, Spealman RD, Isacson O. The blood-brain barrier is intact after levodopa-induced dyskinesias in parkinsonian primates--evidence from in vivo neuroimaging studies. Neurobiology of Disease. 35: 348-51. PMID 19501164 DOI: 10.1016/j.nbd.2009.05.018  0.4
2009 Zhang J, Xu TX, Hallett PJ, Watanabe M, Grant SG, Isacson O, Yao WD. PSD-95 uncouples dopamine-glutamate interaction in the D1/PSD-95/NMDA receptor complex. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 29: 2948-60. PMID 19261890 DOI: 10.1523/JNEUROSCI.4424-08.2009  0.4
2008 Hallett PJ, Collins TL, Standaert DG, Dunah AW. Biochemical fractionation of brain tissue for studies of receptor distribution and trafficking. Current Protocols in Neuroscience / Editorial Board, Jacqueline N. Crawley ... [Et Al.]. Unit 1.16. PMID 18428670 DOI: 10.1002/0471142301.ns0116s42  0.4
2008 Nicholas AP, Lubin FD, Hallett PJ, Vattem P, Ravenscroft P, Bezard E, Zhou S, Fox SH, Brotchie JM, Sweatt JD, Standaert DG. Striatal histone modifications in models of levodopa-induced dyskinesia. Journal of Neurochemistry. 106: 486-94. PMID 18410512 DOI: 10.1111/j.1471-4159.2008.05417.x  0.4
2008 Mendez I, Viñuela A, Astradsson A, Mukhida K, Hallett P, Robertson H, Tierney T, Holness R, Dagher A, Trojanowski JQ, Isacson O. Dopamine neurons implanted into people with Parkinson's disease survive without pathology for 14 years. Nature Medicine. 14: 507-9. PMID 18391961 DOI: 10.1038/nm1752  0.4
2007 Zhang J, Vinuela A, Neely MH, Hallett PJ, Grant SG, Miller GM, Isacson O, Caron MG, Yao WD. Inhibition of the dopamine D1 receptor signaling by PSD-95. The Journal of Biological Chemistry. 282: 15778-89. PMID 17369255 DOI: 10.1074/jbc.M611485200  0.4
2007 Hallett PJ, Brotchie JM. Striatal delta opioid receptor binding in experimental models of Parkinson's disease and dyskinesia. Movement Disorders : Official Journal of the Movement Disorder Society. 22: 28-40. PMID 17089424 DOI: 10.1002/mds.21163  0.4
2006 Hallett PJ, Spoelgen R, Hyman BT, Standaert DG, Dunah AW. Dopamine D1 activation potentiates striatal NMDA receptors by tyrosine phosphorylation-dependent subunit trafficking. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 26: 4690-700. PMID 16641250 DOI: 10.1523/JNEUROSCI.0792-06.2006  0.4
2004 Hallett PJ, Standaert DG. Rationale for and use of NMDA receptor antagonists in Parkinson's disease. Pharmacology & Therapeutics. 102: 155-74. PMID 15163596 DOI: 10.1016/j.pharmthera.2004.04.001  0.4
Show low-probability matches.